Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.95 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.95 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.95 |
| ▸ | MEN1 | O00255 | 3/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.91 |
| ▸ | BLM | P54132 | 4/20 | 0.75 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL99101 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19211133 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL22467689 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL27539194 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL25298399 | 0.98 | CHRM2 (0.95) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6553359 | 0.98 | CHRM2 (0.95) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL22077028 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3301408 | 0.98 | CHRM2 (0.95) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL99102 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL8442770 | 0.98 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123456-A1 | Method for Functionalizing Natural Fatty Substances | Centre National De La Recherche Scienitique (C.N.R.S.) (FR) | 2013-05-16 | — | — | US | claimed |
| EP-0214051-A2 | Benzylamine derivative | MITSUBISHI KASEI CORPORATION (JP) | 1987-03-11 | — | — | EP | claimed |
| JP-3145644-A | — | — | None | — | — | JP | disclosed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | disclosed |
| JP-H03145644-A | DIRECT POSITIVE IMAGE FORMING DEVICE | KONICA CORP | 1991-06-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123456-A1 | Method for Functionalizing Natural Fatty Substances | FASN, ALOX5, FFAR3 | CHRM3 2768/4885CHRM2 3476/4885CHRM5 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.